Q3 2009 Halozyme Earnings Release - Before Market Open

Earnings Announcements for Friday, November 6CompanySymbolTimeConferenceCallA.C. Moore Arts & CraftsACMRBefore Market OpenAARHUSKARLSHAMN ABARHUF.PK02:30 am ETAastrom BiosciencesASTMTime Not SuppliedACE Aviation Holdings, Inc.ACE-A.TOBefore Market OpenAcetoACETBefore Market OpenAchillion Pharmaceuticals Inc.ACHNBefore Market OpenADVANCED CARD SYSTEMS HLDGS8210.HKTime Not SuppliedAdvanced Info Service PLCAVIFY.PKTime Not SuppliedAerCap Holdings N.V.AERBefore Market OpenListenAES CorporationAESBefore Market OpenListenAffirmative Insurance Holdings Inc.AFFMTime Not SuppliedAIRCASTLE LTDAYRBefore Market OpenListenAllied Healthcare ProductsAHPITime Not SuppliedALLIED TECHNOLOGIES LTDA13.SIAfter Market CloseALPIQ HOLDING LTDALPQF.PK01:00 am ETAmerican International GroupAIGBefore Market OpenAMERICAN OIL & GAS I...
Click here to read the whole Article (external link)

HALOZYME THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations As used in this report, unless the context suggests otherwise, the terms "we," "our," "ours," and "us" refer to Halozyme Therapeutics, Inc., and its wholly owned subsidiary, Halozyme, Inc., which are sometimes collectively referred to herein as "the Company." The following information should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report on Form 10-Q. Past financial or operating performance is not necessarily a reliable indicator of future performance, and our historical performance should not be used to anticipate results or future period trends. Except for the historical information contained herein, this report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current forecast of certain aspects of our future. Words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," "think," "may," "could," "will," "would," "should," "continue," "potential," "likely," "opportunity" and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of indentifying forward-looking statements in this report. Additionally, statements concerning future matters such as the development or regulatory approval of new products, enhancements of existing products or technologies, third party performance under key collaboration agreements, revenue and expense levels and other statements regarding matters that are not historical are forward-looking statements. Such statements are based ...
Click here to read the whole Article (external link)

Halozyme Therapeutics Reports Third Quarter 2009 Financial Results

Halozyme Therapeutics, Inc. Condensed Consolidated Statements of Operations     Quarters Ended   Nine Months Ended September 30, September 30, 2009   2008 2009   2008 (unaudited) (unaudited) (unaudited) (unaudited) REVENUES: Revenues under collaboration agreements $ 2,617,776 $ 2,194,325 $ 6,558,145 $ 5,209,897 Product sales   411,109   �...
Click here to read the whole Article (external link)

Halozyme takes bigger loss on testing expenses

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

Halozyme Earnings Call scheduled for 11:00 am ET today

Call DetailsHalozyme Earnings Conference Call (Q3 2009)Fri, Nov 6, 2009, 11:00 am EasternAbout Halozyme (NasdaqGM:HALO)Halozyme Therapeutics, Inc., a biopharmaceutical company, develops and commercializes products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes, known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has partnerships with Roche to apply Enhanze Technology to Roche’s biological therapeutics for up to 13 targets; and with Baxter BioScience to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID. The product candidates in Halozyme’s research pipeline target multiple areas of significant unmet medical need. The company was founded in 1998 and is based in San Diego, California.More Info:Quote |Profile |Reports |Research |Insider |Financials | Analyst Ratings...
Click here to read the whole Article (external link)

HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and

Show all filings for HALOZYME THERAPEUTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for HALOZYME THERAPEUTICS INC 6-Nov-2009Results of Operations and Financial Condition, Financial Statements and Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information...
Click here to read the whole Article (external link)

Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript

Halozyme Therapeutics, Inc. (HALO) Q3 2009 Earnings Call Transcript November 6, 2009 11:00 am ET Executives Robert Uhl – Senior Director, IR Jonathan Lim – President and CEO Kurt Gustafson – VP and CFO Greg Frost – VP and Chief Scientific Officer Analysts Eun Yang – Jefferies & Company Terence Flynn – Lazard Capital Markets Chris Geston – UBS Andrew Vaino – Roth Capital Partners Jonathan Aschoff – Brean Murray, Carret & Co. Presentation Operator Welcome to the Halozyme 2009 third quarter financial results and pipeline update conference call. At this time all participants are in a listen-only mode. Following management’s prepared remarks we will hold a question-and-answer session. (Operator Instructions). As a reminder this conference call is being recorded today, November 6, 2009. I would now like to turn the call over to Robert Uhl. Please go ahead. Robert Uhl Thank you, Adrian, and thanks also to everyone for participating in today’s call. I’m Robert Uhl, Senior Director of Investor Relations at Halozyme Therapeutics. Joining me on the call today from Halozyme are Jonathan Lim, President and Chief Executive Officer, and Kurt Gustafson, Chief Financial Officer. Additional members of the Halozyme management team will also be available to address your questions during the Q&A portion of the call. This morning Halozyme released 2009 third quarter financial results. If you have not received this news release or if you would like to be added to the company’s distribution list please call Alex Schlam [ph] at 858-704-8288. This call is also being webcast live over the Internet at ...
Click here to read the whole Article (external link)

Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme

SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq:HALO - News) today announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro alone. When compared to lispro alone, the combination of lispro with PH20 reduced the variability for early and late insulin absorption, the time to maximum concentration (Tmax), and the area under the curve (AUC) at 15, 30, 60 and 120 minutes. The variability for maximum concentration (Cmax) was not affected. In addition, study results confirmed previously reported acceleration for both insulin absorption and action by coadministration of PH20. The company presented these study results this evening at the Diabetes Technology Society meeting in San Francisco. “Reduced variability for the combination of lispro with PH20 across a number of key pharmacokinetic measures, especially during the first two hours after administra...
Click here to read the whole Article (external link)

New Star Analyst Rankings for Halozyme Therapeutics, Inc.

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...
Click here to read the whole Article (external link)

HALOZYME THERAPEUTICS INC Financials

PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue3,029  1,426  2,772  3,062  Cost of Revenue103  45  4  127  Gross Profit2,926  1,381  2,768  2,935  Operating ExpensesResearch Development13,163  14,561  14,040  16,782  Selling General and Administrative3,703  3,904  3,487  3,179  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss(13,940)(17,084)(14,759)(17,027)Income from Continuing OperationsTotal Other Income/Expenses Net29  24  33  138  Earnings Before Interest And Taxes(13,910)(17,060)(14,725)(16,889)Interest Expense -   -   -   -  Income Before Tax(13,910)(17,060)(14,725)(16,889)Income Tax Expense -   -   -  (63)Minority Interest -   -   -   -  Net Income From Continuing Ops(13,910)(17,060)(14,725)(16,826)Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   -   -   - ...
Click here to read the whole Article (external link)